Corbus Pharmaceuticals Holdings Inc (CRBP) — Titan Protect Analysis

CRBP

Corbus Pharmaceuticals Holdings Inc

Healthcare · ·

$7.56

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$142M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-1.51

Based on estimated future earnings — lower means cheaper

Rev Growth

N/A

Year-over-year revenue change

Profit Margin

N/A

How much profit the company keeps from each dollar of revenue

ROE

-66.7%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$37.00

+389% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 10 analysts covering this stock

About Corbus Pharmaceuticals Holdings Inc

Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity. The company was incorporated in 2009 and is headquartered in Norwood, Massachusetts.

https://www.corbuspharma.com

Country: United States Employees: 36 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

DISTRIBUTION

Smart money appears to be selling into strength — caution

Sharpe Ratio

-0.429

Returns do not compensate for the risk — negative edge

Kelly Fraction

-0.0583

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.641

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-58.9%

Historical annualised return based on price data

Max Drawdown

-92.0%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

2.68

Significantly more volatile than the market

52W High

$20.56

63% below the year high

52W Low

$6.72

12% above the year low

Avg Volume

395,515

Average daily shares traded — higher means easier to buy and sell

Short Ratio

3.9

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-5.74

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

0.95

Moderate leverage — manageable

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

N/A

Revenue left after cost of goods — higher means pricing power

Operating Margin

N/A

Profit from core operations before interest and tax

Free Cash Flow

$-43,282,376

Negative — the business is spending more than it generates

Revenue (TTM)

N/A

Total revenue over the last 12 months

Net Income

$-84,528,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$54.00

Target Median

$37.00

Target Low

$17.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go